Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | PF-06801591 |
Synonyms | |
Therapy Description |
PF-06801591 (sasanlimab) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 32847983). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PF-06801591 | PF06801591|PF 06801591|Sasanlimab | Immune Checkpoint Inhibitor 146 PD-L1/PD-1 antibody 115 | PF-06801591 (sasanlimab) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 32847983). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 over exp | Advanced Solid Tumor | predicted - sensitive | PF-06801591 | Phase I | Actionable | In a Phase I trial, treatment with PF-06801591 resulted in a greater overall objective response in patients with an advanced solid tumor and higher CD274 expression (n=10), including four partial responses and two patients with stable disease, compared to those patients with lower CD274 expression (n=20), which included one partial response and ten patients with stable disease (PMID: 31145415; NCT02573259). | 31145415 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05241340 | Phase II | PF-06801591 | Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer (RAD-VACCINE) | Recruiting | USA | 0 |
NCT02573259 | Phase I | PF-06801591 | A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors | Completed | USA | 6 |